Home > Nicotine receptor partial agonists for smoking cessation.

Livingstone-Banks, Jonathan and Fanshawe, Thomas R and Thomas, Kyla H and Theodoulou, Annika and Hajizadeh, Anisa and Hartman, Lilian and Lindson, Nicola (2023) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, (5), Art. no.: CD006103. DOI: 10.1002/14651858.CD006103.pub8.

External website: https://www.cochranelibrary.com/cdsr/doi/10.1002/1...

Authors' conclusions:
Cytisine and varenicline both help more people to quit smoking than placebo or no medication. Varenicline is more effective at helping people to quit smoking than bupropion, or a single form of NRT, and may be as or more effective than dual‐form NRT. People taking varenicline are probably more likely to experience SAEs than those not taking it, and while there may be increased risk of cardiac SAEs and decreased risk of neuropsychiatric SAEs, evidence was compatible with both benefit and harm. Cytisine may lead to fewer people reporting SAEs than varenicline. Based on studies that directly compared cytisine and varenicline, there may be a benefit from varenicline for quitting smoking, however further evidence could strengthen this finding or demonstrate a benefit from cytisine.

Future trials should test the effectiveness and safety of cytisine compared with varenicline and other pharmacotherapies, and should also test variations in dose and duration. There is limited benefit to be gained from more trials testing the effect of standard‐dose varenicline compared with placebo for smoking cessation. Further trials on varenicline should test variations in dose and duration, and compare varenicline with e‐cigarettes for smoking cessation.

Item Type
Publication Type
International, Review, Article
Drug Type
Tobacco / Nicotine
Intervention Type
Drug therapy, Treatment method
May 2023
Identification #
DOI: 10.1002/14651858.CD006103.pub8
John Wiley & Sons, Ltd
Place of Publication

Repository Staff Only: item control page